Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 5.482
Filter
1.
AIDS Res Ther ; 21(1): 37, 2024 Jun 06.
Article in English | MEDLINE | ID: mdl-38844950

ABSTRACT

INTRODUCTION: Despite the widespread use of pre-exposure prophylaxis (PrEP) in preventing human immunodeficiency virus (HIV) transmission, scant information on HIV drug resistance mutations (DRMs) has been gathered over the past decade. This review aimed to estimate the pooled prevalence of pre-exposure prophylaxis and its two-way impact on DRM. METHODS: We systematically reviewed studies on DRM in pre-exposure prophylaxis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 guidelines. PubMed, Cochrane, and SAGE databases were searched for English-language primary studies published between January 2001 and December 2023. The initial search was conducted on 9 August 2021 and was updated through 31 December 2023 to ensure the inclusion of the most recent findings. The registration number for this protocol review was CRD42022356061. RESULTS: A total of 26,367 participants and 562 seroconversion cases across 12 studies were included in this review. The pooled prevalence estimate for all mutations was 6.47% (95% Confidence Interval-CI 3.65-9.93), while Tenofovir Disoproxil Fumarate/Emtricitabine-associated drug resistance mutation prevalence was 1.52% (95% CI 0.23-3.60) in the pre-exposure prophylaxis arm after enrolment. A subgroup analysis, based on the study population, showed the prevalence in the heterosexual and men who have sex with men (MSM) groups was 5.53% (95% CI 2.55-9.40) and 7.47% (95% CI 3.80-12.11), respectively. Notably, there was no significant difference in the incidence of DRM between the pre-exposure prophylaxis and placebo groups (log-OR = 0.99, 95% CI -0.20 to 2.18, I2 = 0%; p = 0.10). DISCUSSION: Given the constrained prevalence of DRM, the World Health Organization (WHO) advocates the extensive adoption of pre-exposure prophylaxis. Our study demonstrated no increased risk of DRM with pre-exposure prophylaxis (p > 0.05), which is consistent with these settings. These findings align with the previous meta-analysis, which reported a 3.14-fold higher risk in the pre-exposure prophylaxis group than the placebo group, although the observed difference did not reach statistical significance (p = 0.21). CONCLUSIONS: Despite the low prevalence of DRM, pre-exposure prophylaxis did not significantly increase the risk of DRM compared to placebo. However, long-term observation is required to determine further disadvantages of extensive pre-exposure prophylaxis use. PROSPERO Number: CRD42022356061.


Subject(s)
Anti-HIV Agents , Drug Resistance, Viral , HIV Infections , HIV-1 , Mutation , Pre-Exposure Prophylaxis , Humans , HIV Infections/prevention & control , HIV Infections/virology , HIV Infections/drug therapy , Drug Resistance, Viral/genetics , Anti-HIV Agents/therapeutic use , Anti-HIV Agents/administration & dosage , HIV-1/drug effects , HIV-1/genetics , Male , Administration, Oral , Female , Tenofovir/therapeutic use , Tenofovir/administration & dosage , Prevalence
2.
Sci Rep ; 14(1): 10620, 2024 05 09.
Article in English | MEDLINE | ID: mdl-38724547

ABSTRACT

Although most people living with HIV (PLWH) receiving antiretroviral therapy (ART) achieve continuous viral suppression, some show detectable HIV RNA as low-level viremia (LLV) (50-999 copies/mL). Drug resistance mutations (DRMs) in PLWH with LLV is of particular concern as which may lead to treatment failure. In this study, we investigated the prevalence of LLV and LLV-associated DRMs in PLWH in Zhengzhou City, China. Of 3616 ART-experienced PLWH in a long-term follow-up cohort from Jan 2022 to Aug 2023, 120 were identified as having LLV. Of these PLWH with LLV, we obtained partial pol and integrase sequences from 104 (70 from HIV-1 RNA and 34 from proviral DNA) individuals. DRMs were identified in 44 individuals. Subtyping analysis indicated that the top three subtypes were B (48.08%, 50/104), CRF07_BC (31.73%, 33/104), and CRF01_AE (15.38%, 16/104). The proportions of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs) associated DRMs were 23.83% (24/104), 35.58% (37/104), 5.77% (6/104), and 3.85% (4/104), respectively, which contributed to an overall prevalence of 42.31% (44/104). When analyzed by individual DRMs, the most common mutation(s) were V184 (18.27%, 19/104), followed by V179 (11.54%, 12/104), K103 (9.62%, 10/104), Y181 (9.62%, 10/104), M41 (7.69%, 8/104), and K65R (7.69%, 8/104). The prevalence of DRMs in ART-experienced PLWH with LLV is high in Zhengzhou City and continuous surveillance can facilitate early intervention and provision of effective treatment.


Subject(s)
Drug Resistance, Viral , HIV Infections , HIV-1 , Mutation , Viremia , Humans , HIV-1/genetics , HIV-1/drug effects , HIV Infections/drug therapy , HIV Infections/virology , HIV Infections/epidemiology , China/epidemiology , Drug Resistance, Viral/genetics , Male , Female , Viremia/drug therapy , Viremia/epidemiology , Adult , Middle Aged , Anti-HIV Agents/therapeutic use , Anti-HIV Agents/pharmacology , RNA, Viral/genetics
3.
Biol Pharm Bull ; 47(5): 967-977, 2024.
Article in English | MEDLINE | ID: mdl-38763751

ABSTRACT

Ensitrelvir is a noncovalent inhibitor of the main protease (Mpro) of severe acute respiratory syndrome coronavirus 2. Acquisition of drug resistance in virus-derived proteins is a serious therapeutic concern, and drug resistance occurs due to amino acid mutations. In this study, we computationally constructed 24 mutants, in which one residue around the active site was replaced with alanine and performed molecular dynamics simulations to the complex of Mpro and ensitrelvir to predict the residues involved in drug resistance. We evaluated the changes in the entire protein structure and ligand configuration in each of these mutants and estimated which residues were involved in ensitrelvir recognition. This method is called a virtual alanine scan. In nine mutants (S1A, T26A, H41A, M49A, L141A, H163A, E166A, V186A, and R188A), although the entire protein structure and catalytic dyad (cysteine (Cys)145 and histidine (His)41) were not significantly moved, the ensitrelvir configuration changed. Thus, it is considered that these mutants did not recognize ensitrelvir while maintaining Mpro enzymatic activities, and Ser1, Thr26, His41, Met49, Leu141, His163, Glu166, Val186, and Arg188 may be related to ensitrelvir resistance. The ligand shift noted in M49A was similar to that observed in M49I, which has been shown to be experimentally ensitrelvir resistant. These findings suggest that our research approach can predict mutations that incite drug resistance.


Subject(s)
Alanine , Catalytic Domain , Coronavirus 3C Proteases , Drug Resistance, Viral , Molecular Dynamics Simulation , SARS-CoV-2 , Coronavirus 3C Proteases/metabolism , Coronavirus 3C Proteases/genetics , Coronavirus 3C Proteases/antagonists & inhibitors , Coronavirus 3C Proteases/chemistry , SARS-CoV-2/drug effects , Alanine/genetics , Drug Resistance, Viral/genetics , Humans , Mutation , COVID-19 Drug Treatment , Protease Inhibitors/pharmacology , Indazoles , Triazines , Triazoles
4.
Sci Rep ; 14(1): 10742, 2024 05 10.
Article in English | MEDLINE | ID: mdl-38730249

ABSTRACT

The selection pressure imposed by the host immune system impacts on hepatitis B virus (HBV) variability. This study evaluates HBV genetic diversity, nucleos(t)ide analogs resistance and HBsAg escape mutations in HBV patients under distinct selective pressures. One hundred and thirteen individuals in different phases of HBV infection were included: 13 HBeAg-positive chronic infection, 9 HBeAg-positive chronic hepatitis, 47 HBeAg-negative chronic infection (ENI), 29 HBeAg-negative chronic hepatitis (ENH) and 15 acute infected individuals. Samples were PCR amplified, sequenced and genetically analyzed for the overlapping POL/S genes. Most HBV carriers presented genotype A (84/113; 74.3%), subgenotype A1 (67/84; 79.7%), irrespective of group, followed by genotypes D (20/113; 17.7%), F (8/113; 7.1%) and E (1/113; 0.9%). Clinically relevant mutations in polymerase (tL180M/M204V) and in the Major Hydrophilic Region of HBsAg (sY100C, T118A/M, sM133T, sD144A and sG145R) were observed. Our findings, however, indicated that most polymorphic sites were located in the cytosolic loops (CYL1-2) and transmembrane domain 4 (TMD4) of HBsAg. Lower viral loads and higher HBV genetic diversity were observed in ENI and ENH groups (p < 0.001), suggesting that these groups are subjected to a higher selective pressure. Our results provide information on the molecular characteristics of HBV in a diverse clinical setting, and may guide future studies on the balance of HBV quasispecies at different stages of infection.


Subject(s)
Genetic Variation , Genotype , Hepatitis B Surface Antigens , Hepatitis B virus , Hepatitis B, Chronic , Humans , Hepatitis B virus/genetics , Hepatitis B, Chronic/virology , Hepatitis B, Chronic/genetics , Brazil/epidemiology , Male , Adult , Female , Middle Aged , Hepatitis B Surface Antigens/genetics , Mutation , Drug Resistance, Viral/genetics , DNA, Viral/genetics , Young Adult , Phylogeny , Hepatitis B e Antigens/genetics
5.
Sci Rep ; 14(1): 12099, 2024 05 27.
Article in English | MEDLINE | ID: mdl-38802662

ABSTRACT

HIV-1 drug resistance genotypic tests have primarily been performed by Sanger sequencing of gene segments encoding different drug target proteins. Since the number of targets has increased with the addition of a new class of antiretroviral drugs, a simple high-throughput system for assessing nucleotide sequences throughout the HIV-1 genome is required. Here, we developed a new solution using nanopore sequencing of viral pangenomes amplified by PCR. Benchmark tests using HIV-1 molecular clones demonstrated an accuracy of up to 99.9%. In addition, validation tests of our protocol in 106 clinical samples demonstrated high concordance of drug resistance and tropism genotypes (92.5% and 98.1%, respectively) between the nanopore sequencing-based results and archived clinical determinations made based on Sanger sequencing data. These results suggest that our new approach will be a powerful solution for the comprehensive survey of HIV-1 drug resistance mutations in clinical settings.


Subject(s)
Drug Resistance, Viral , Genome, Viral , HIV Infections , HIV-1 , Mutation , Nanopore Sequencing , HIV-1/genetics , HIV-1/drug effects , Drug Resistance, Viral/genetics , Nanopore Sequencing/methods , Humans , HIV Infections/virology , HIV Infections/drug therapy , Genotype , Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use , High-Throughput Nucleotide Sequencing/methods
6.
Viruses ; 16(5)2024 04 28.
Article in English | MEDLINE | ID: mdl-38793578

ABSTRACT

The Vietnam Ministry of Health (MOH) has intensified efforts in its aim to eliminate AIDS by 2030. Expanding the program for prevention of mother-to-child transmission (PMTCT) is a significant step towards achieving this goal. However, there are still HIV-exposed children who do not have access to PMTCT services, and some who have participated in the program but still contracted HIV. This study focused on assessing the prevalence and profile of HIV mutations among children under 18 months of age who had recently tested positive for HIV, while gaining insights into the implementation of early infant diagnostic (EID) tests. Between 2017 and 2021, 3.43% of 5854 collected dry blood spot (DBS) specimens from Vietnam's Central and Southern regions showed positive EID results. This study identified a high prevalence of resistance mutations in children, totaling 62.9% (95% CI: 53.5-72.3). The highest prevalence of mutations was observed for NNRTIs, with 57.1% (95% CI: 47.5-66.8). Common mutations included Y181C and K103N (NNRTI resistance), M184I/V (NRTI resistance), and no major mutations for PI. The percentage of children with any resistance mutation was significantly higher among those who received PMTCT interventions (69.2%; 95% CI: 50.5-92.6%) compared with those without PMTCT (45.0%; 95% CI: 26.7-71.1%) with χ2 = 6.06, p = 0.0138, and OR = 2.75 (95% CI: 1.13-6.74). Mutation profiles revealed that polymorphic mutations could be present regardless of whether PMTCT interventions were implemented or not. However, non-polymorphic drug resistance mutations were predominantly observed in children who received PMTCT measures. Regarding PMTCT program characteristics, this study highlights the issue of late access to HIV testing for both mothers and their infected children. Statistical differences were observed between PMTCT and non-PMTCT children. The proportion of late detection of HIV infection and breastfeeding rates were significantly higher among non-PMTCT children (p < 0.05). Comparative analysis between children with low viral load (≤200 copies/mL) and high viral load (>200 copies/mL) showed significant differences between the mothers' current ART regimens (p = 0.029) and the ARV prophylaxis regimen for children (p = 0.016). These findings emphasize the need for comprehensive surveillance to assess the effectiveness of the PMTCT program, including potential transmission of HIV drug-resistance mutations from mothers to children in Vietnam.


Subject(s)
Drug Resistance, Viral , HIV Infections , HIV-1 , Infectious Disease Transmission, Vertical , Mutation , Humans , HIV Infections/transmission , HIV Infections/epidemiology , HIV Infections/virology , HIV Infections/prevention & control , Infectious Disease Transmission, Vertical/prevention & control , Vietnam/epidemiology , Drug Resistance, Viral/genetics , HIV-1/genetics , HIV-1/drug effects , Female , Infant , Male , Anti-HIV Agents/therapeutic use , Prevalence , Infant, Newborn , Pregnancy
7.
Viruses ; 16(5)2024 04 30.
Article in English | MEDLINE | ID: mdl-38793600

ABSTRACT

Although the coronavirus disease 2019 (COVID-19) pandemic is coming to an end, it still poses a threat to the immunocompromised and others with underlying diseases. Especially in cases of persistent COVID-19, new mutations conferring resistance to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapies have considerable clinical implications. We present a patient who independently acquired a T21I mutation in the 3CL protease after nirmatrelvir exposure. The T21I mutation in the 3CL protease is one of the most frequent mutations responsible for nirmatrelvir resistance. However, limited reports exist on actual cases of SARS-CoV-2 with T21I and other mutations in the 3CL protease. The patient, a 55 year-old male, had COVID-19 during chemotherapy for multiple myeloma. He was treated with nirmatrelvir early in the course of the disease but relapsed, and SARS-CoV-2 with a T21I mutation in the 3CL protease was detected in nasopharyngeal swab fluid. The patient had temporary respiratory failure but later recovered well. During treatment with remdesivir and dexamethasone, viruses with the T21I mutation in the 3CL protease showed a decreasing trend during disease progression while increasing during improvement. The impact of drug-resistant SARS-CoV-2 on the clinical course, including its severity, remains unknown. Our study is important for examining the clinical impact of nirmatrelvir resistance in COVID-19.


Subject(s)
Antiviral Agents , COVID-19 , Drug Resistance, Viral , Immunocompromised Host , SARS-CoV-2 , Humans , Middle Aged , Male , SARS-CoV-2/genetics , SARS-CoV-2/drug effects , SARS-CoV-2/immunology , Drug Resistance, Viral/genetics , Antiviral Agents/therapeutic use , Antiviral Agents/pharmacology , COVID-19/immunology , COVID-19/virology , Mutation , Multiple Myeloma/drug therapy , Coronavirus 3C Proteases/genetics , COVID-19 Drug Treatment , Alanine/analogs & derivatives , Alanine/therapeutic use
8.
Bioinformatics ; 40(6)2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38775719

ABSTRACT

MOTIVATION: In predicting HIV therapy outcomes, a critical clinical question is whether using historical information can enhance predictive capabilities compared with current or latest available data analysis. This study analyses whether historical knowledge, which includes viral mutations detected in all genotypic tests before therapy, their temporal occurrence, and concomitant viral load measurements, can bring improvements. We introduce a method to weigh mutations, considering the previously enumerated factors and the reference mutation-drug Stanford resistance tables. We compare a model encompassing history (H) with one not using this information (NH). RESULTS: The H-model demonstrates superior discriminative ability, with a higher ROC-AUC score (76.34%) than the NH-model (74.98%). Wilcoxon test results confirm significant improvement of predictive accuracy for treatment outcomes through incorporating historical information. The increased performance of the H-model might be attributed to its consideration of latent HIV reservoirs, probably obtained when leveraging historical information. The findings emphasize the importance of temporal dynamics in acquiring mutations. However, our result also shows that prediction accuracy remains relatively high even when no historical information is available. AVAILABILITY AND IMPLEMENTATION: This analysis was conducted using the Euresist Integrated DataBase (EIDB). For further validation, we encourage reproducing this study with the latest release of the EIDB, which can be accessed upon request through the Euresist Network.


Subject(s)
HIV Infections , HIV-1 , Mutation , HIV-1/genetics , Humans , HIV Infections/drug therapy , HIV Infections/virology , Drug Resistance, Viral/genetics , Viral Load , Anti-HIV Agents/therapeutic use , Anti-HIV Agents/pharmacology , Treatment Outcome
9.
Proc Natl Acad Sci U S A ; 121(15): e2316662121, 2024 Apr 09.
Article in English | MEDLINE | ID: mdl-38557187

ABSTRACT

Drug resistance in HIV type 1 (HIV-1) is a pervasive problem that affects the lives of millions of people worldwide. Although records of drug-resistant mutations (DRMs) have been extensively tabulated within public repositories, our understanding of the evolutionary kinetics of DRMs and how they evolve together remains limited. Epistasis, the interaction between a DRM and other residues in HIV-1 protein sequences, is key to the temporal evolution of drug resistance. We use a Potts sequence-covariation statistical-energy model of HIV-1 protein fitness under drug selection pressure, which captures epistatic interactions between all positions, combined with kinetic Monte-Carlo simulations of sequence evolutionary trajectories, to explore the acquisition of DRMs as they arise in an ensemble of drug-naive patient protein sequences. We follow the time course of 52 DRMs in the enzymes protease, RT, and integrase, the primary targets of antiretroviral therapy. The rates at which DRMs emerge are highly correlated with their observed acquisition rates reported in the literature when drug pressure is applied. This result highlights the central role of epistasis in determining the kinetics governing DRM emergence. Whereas rapidly acquired DRMs begin to accumulate as soon as drug pressure is applied, slowly acquired DRMs are contingent on accessory mutations that appear only after prolonged drug pressure. We provide a foundation for using computational methods to determine the temporal evolution of drug resistance using Potts statistical potentials, which can be used to gain mechanistic insights into drug resistance pathways in HIV-1 and other infectious agents.


Subject(s)
Anti-HIV Agents , HIV Infections , HIV Seropositivity , HIV-1 , Humans , HIV-1/genetics , Drug Resistance, Viral/genetics , Genotype , HIV Infections/drug therapy , HIV Infections/genetics , Mutation , Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use
10.
Viruses ; 16(4)2024 04 11.
Article in English | MEDLINE | ID: mdl-38675933

ABSTRACT

(1) Background: We aimed to determine the prevalence of hepatitis B virus (HBV) resistance-associated mutations (RAMs) in people with HBV and human immunodeficiency virus (HBV/HIV) in Botswana. (2) Methods: We sequenced HBV deoxyribonucleic acid (DNA) from participants with HBV/HIV from the Botswana Combination Prevention Project study (2013-2018) using the Oxford Nanopore GridION platform. Consensus sequences were analyzed for genotypic and mutational profiles. (3) Results: Overall, 98 HBV sequences had evaluable reverse transcriptase region coverage. The median participant age was 43 years (IQR: 37, 49) and 66/98 (67.4%) were female. Most participants, i.e., 86/98 (87.8%) had suppressed HIV viral load (VL). HBV RAMs were identified in 61/98 (62.2%) participants. Most RAMs were in positions 204 (60.3%), 180 (50.5%), and 173 (33.3%), mostly associated with lamivudine resistance. The triple mutations rtM204V/L180M/V173L were the most predominant (17/61 [27.9%]). Most participants (96.7%) with RAMs were on antiretroviral therapy for a median duration of 7.5 years (IQR: 4.8, 10.5). Approximately 27.9% (17/61) of participants with RAMs had undetectable HBV VL, 50.8% (31/61) had VL < 2000 IU/mL, and 13/61 (21.3%) had VL ≥ 2000 IU/mL. (4) Conclusions: The high prevalence of lamivudine RAMs discourages the use of ART regimens with 3TC as the only HBV-active drug in people with HIV/HBV.


Subject(s)
Coinfection , Drug Resistance, Viral , HIV Infections , Hepatitis B virus , Hepatitis B , Lamivudine , Mutation , Humans , Hepatitis B virus/genetics , Hepatitis B virus/drug effects , HIV Infections/virology , HIV Infections/drug therapy , HIV Infections/epidemiology , Female , Drug Resistance, Viral/genetics , Male , Botswana/epidemiology , Lamivudine/therapeutic use , Lamivudine/pharmacology , Adult , Middle Aged , Prevalence , Coinfection/virology , Coinfection/epidemiology , Coinfection/drug therapy , Hepatitis B/virology , Hepatitis B/epidemiology , Hepatitis B/drug therapy , Rural Population , Viral Load , Genotype , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use
11.
Viruses ; 16(4)2024 04 17.
Article in English | MEDLINE | ID: mdl-38675962

ABSTRACT

BACKGROUND: The global scale-up of antiretroviral treatment (ART) offers significant health benefits by suppressing HIV-1 replication and increasing CD4 cell counts. However, incomplete viral suppression poses a potential threat for the emergence of drug resistance mutations (DRMs), limiting ART options, and increasing HIV transmission. OBJECTIVE: We investigated the patterns of transmitted drug resistance (TDR) and acquired drug resistance (ADR) among HIV-1 patients in Portugal. METHODS: Data were obtained from 1050 HIV-1 patient samples submitted for HIV drug resistance (HIVDR) testing from January 2022 to June 2023. Evaluation of DRM affecting viral susceptibility to nucleoside/tide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs) was performed using an NGS technology, the Vela Diagnostics Sentosa SQ HIV-1 Genotyping Assay. RESULTS: About 71% of patients were ART naïve and 29% were experienced. Overall, 20% presented with any DRM. The prevalence of TDR and ADR was 12.6% and 41.1%, respectively. M184V, T215S, and M41L mutations for NRTI, K103N for NNRTI, and M46I/L for PIs were frequent in naïve and treated patients. E138K and R263K mutations against INSTIs were more frequent in naïve than treated patients. TDR and ADR to INSTIs were 0.3% and 7%, respectively. Patients aged 50 or over (OR: 1.81, p = 0.015), originating from Portuguese-speaking African countries (PALOPs) (OR: 1.55, p = 0.050), HIV-1 subtype G (OR: 1.78, p = 0.010), and with CD4 < 200 cells/mm3 (OR: 1.70, p = 0.043) were more likely to present with DRMs, while the males (OR: 0.63, p = 0.003) with a viral load between 4.1 to 5.0 Log10 (OR: 0.55, p = 0.003) or greater than 5.0 Log10 (OR: 0.52, p < 0.001), had lower chances of presenting with DRMs. CONCLUSIONS: We present the first evidence on TDR and ADR to INSTI regimens in followed up patients presenting for healthcare in Portugal. We observed low levels of TDR to INSTIs among ART-naïve and moderate levels in ART-exposed patients. Regimens containing PIs could be an alternative second line in patients with intermediate or high-level drug resistance, especially against second-generation INSTIs (dolutegravir, bictegravir, and cabotegravir).


Subject(s)
Anti-HIV Agents , Drug Resistance, Viral , HIV Infections , HIV-1 , High-Throughput Nucleotide Sequencing , Mutation , Humans , HIV-1/genetics , HIV-1/drug effects , Portugal/epidemiology , HIV Infections/virology , HIV Infections/drug therapy , HIV Infections/epidemiology , Drug Resistance, Viral/genetics , Male , Female , Middle Aged , Adult , Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use , Genotype , Reverse Transcriptase Inhibitors/pharmacology , Reverse Transcriptase Inhibitors/therapeutic use , Young Adult , Aged
12.
Nat Commun ; 15(1): 3644, 2024 Apr 29.
Article in English | MEDLINE | ID: mdl-38684655

ABSTRACT

Despite expanded antiretroviral therapy (ART) in South Africa, HIV-1 transmission persists. Integrase strand transfer inhibitors (INSTI) and long-acting injectables offer potential for superior viral suppression, but pre-existing drug resistance could threaten their effectiveness. In a community-based study in rural KwaZulu-Natal, prior to widespread INSTI usage, we enroled 18,025 individuals to characterise HIV-1 drug resistance and transmission networks to inform public health strategies. HIV testing and reflex viral load quantification were performed, with deep sequencing (20% variant threshold) used to detect resistance mutations. Phylogenetic and geospatial analyses characterised transmission clusters. One-third of participants were HIV-positive, with 21.7% having detectable viral loads; 62.1% of those with detectable viral loads were ART-naïve. Resistance to older reverse transcriptase (RT)-targeting drugs was found, but INSTI resistance remained low (<1%). Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, particularly to rilpivirine (RPV) even in ART-naïve individuals, was concerning. Twenty percent of sequenced individuals belonged to transmission clusters, with geographic analysis highlighting higher clustering in peripheral and rural areas. Our findings suggest promise for INSTI-based strategies in this setting but underscore the need for RPV resistance screening before implementing long-acting cabotegravir (CAB) + RPV. The significant clustering emphasises the importance of geographically targeted interventions to effectively curb HIV-1 transmission.


Subject(s)
Drug Resistance, Viral , HIV Infections , HIV-1 , Phylogeny , Rural Population , Viral Load , Humans , HIV Infections/transmission , HIV Infections/drug therapy , HIV Infections/virology , HIV Infections/epidemiology , Drug Resistance, Viral/genetics , South Africa/epidemiology , HIV-1/genetics , HIV-1/drug effects , Female , Male , Adult , Middle Aged , Viral Load/drug effects , Young Adult , Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use , Adolescent , Mutation , Reverse Transcriptase Inhibitors/therapeutic use , Reverse Transcriptase Inhibitors/pharmacology , HIV Integrase Inhibitors/pharmacology , HIV Integrase Inhibitors/therapeutic use
13.
Nat Commun ; 15(1): 3604, 2024 Apr 29.
Article in English | MEDLINE | ID: mdl-38684722

ABSTRACT

Numerous SARS-CoV-2 variant strains with altered characteristics have emerged since the onset of the COVID-19 pandemic. Remdesivir (RDV), a ribonucleotide analogue inhibitor of viral RNA polymerase, has become a valuable therapeutic agent. However, immunosuppressed hosts may respond inadequately to RDV and develop chronic persistent infections. A patient with respiratory failure caused by interstitial pneumonia, who had undergone transplantation of the left lung, developed COVID-19 caused by Omicron BA.5 strain with persistent chronic viral shedding, showing viral fusogenicity. Genome-wide sequencing analyses revealed the occurrence of several viral mutations after RDV treatment, followed by dynamic changes in the viral populations. The C799F mutation in nsp12 was found to play a pivotal role in conferring RDV resistance, preventing RDV-triphosphate from entering the active site of RNA-dependent RNA polymerase. The occurrence of diverse mutations is a characteristic of SARS-CoV-2, which mutates frequently. Herein, we describe the clinical case of an immunosuppressed host in whom inadequate treatment resulted in highly diverse SARS-CoV-2 mutations that threatened the patient's health due to the development of drug-resistant variants.


Subject(s)
Adenosine Monophosphate/analogs & derivatives , Alanine , Alanine/analogs & derivatives , COVID-19 , Coronavirus RNA-Dependent RNA Polymerase , Lung Transplantation , Mutation , SARS-CoV-2 , Humans , SARS-CoV-2/genetics , COVID-19/virology , Alanine/therapeutic use , Male , Antiviral Agents/therapeutic use , Immunocompromised Host , Adenosine Monophosphate/therapeutic use , Drug Resistance, Viral/genetics , Middle Aged , COVID-19 Drug Treatment , Lung Diseases, Interstitial/genetics , Lung Diseases, Interstitial/virology
14.
Antimicrob Agents Chemother ; 68(5): e0011024, 2024 May 02.
Article in English | MEDLINE | ID: mdl-38619252

ABSTRACT

Ocular herpes simplex virus 1 (HSV-1) infections can lead to visual impairment. Long-term acyclovir (ACV) prophylaxis reduces the frequency of recurrences but is associated with drug resistance. Novel therapies are needed to treat drug-resistant HSV-1 infections. Here, we describe the effects of trifluridine (TFT) in combination with ACV or ganciclovir (GCV) on HSV-1 replication and drug-resistance emergence. Wild-type HSV-1 was grown under increasing doses of one antiviral (ACV, GCV, or TFT) or combinations thereof (ACV + TFT or GCV + TFT). Virus cultures were analyzed by Sanger sequencing and deep sequencing of the UL23 [thymidine kinase (TK)] and UL30 [DNA polymerase (DP)] genes. The phenotypes of novel mutations were determined by cytopathic effect reduction assays. TFT showed overall additive anti-HSV-1 activity with ACV and GCV. Five passages under ACV, GCV, or TFT drug pressure gave rise to resistance mutations, primarily in the TK. ACV + TFT and GCV + TFT combinatory pressure induced mutations in the TK and DP. The DP mutations were mainly located in terminal regions, outside segments that typically carry resistance mutations. TK mutations (R163H, A167T, and M231I) conferring resistance to all three nucleoside analogs (ACV, TFT, and GCV) emerged under ACV, TFT, ACV + TFT pressure and under GCV + TFT pressure initiated from suboptimal drug concentrations. However, higher doses of GCV and TFT prevented drug resistance in the resistance selection experiments. In summary, we identified novel mutations conferring resistance to nucleoside analogs, including TFT, and proposed that GCV + TFT combination therapy may be an effective strategy to prevent the development of drug resistance.


Subject(s)
Acyclovir , Antiviral Agents , Drug Resistance, Viral , Ganciclovir , Herpesvirus 1, Human , Trifluridine , Herpesvirus 1, Human/drug effects , Herpesvirus 1, Human/genetics , Trifluridine/pharmacology , Ganciclovir/pharmacology , Antiviral Agents/pharmacology , Drug Resistance, Viral/genetics , Drug Resistance, Viral/drug effects , Vero Cells , Acyclovir/pharmacology , Chlorocebus aethiops , Thymidine Kinase/genetics , Animals , Virus Replication/drug effects , Humans , Mutation , DNA-Directed DNA Polymerase/genetics , Herpes Simplex/drug therapy , Herpes Simplex/virology
15.
Int J Biol Macromol ; 267(Pt 2): 131629, 2024 May.
Article in English | MEDLINE | ID: mdl-38631585

ABSTRACT

Current management of HCV infection is based on Direct-Acting Antiviral Drugs (DAAs). However, resistance-associated mutations, especially in the NS3 and NS5B regions are gradually decreasing the efficacy of DAAs. Among the most effective HCV NS3/4A protease drugs, Sofosbuvir also develops resistance due to mutations in the NS3 and NS5B regions. Four mutations at positions A156Y, L36P, Q41H, and Q80K are classified as high-level resistance mutations. The resistance mechanism of HCV NS3/4A protease toward Sofosbuvir caused by these mutations is still unclear, as there is less information available regarding the structural and functional effects of the mutations against Sofosbuvir. In this work, we combined molecular dynamics simulation, molecular mechanics/Generalized-Born surface area calculation, principal component analysis, and free energy landscape analysis to explore the resistance mechanism of HCV NS3/4A protease due to these mutations, as well as compare interaction changes in wild-type. Subsequently, we identified that the mutant form of HCV NS3/4A protease affects the activity of Sofosbuvir. In this study, the resistance mechanism of Sofosbuvir at the atomic level is proposed. The proposed drug-resistance mechanism will provide valuable guidance for the design of HCV drugs.


Subject(s)
Antiviral Agents , Drug Resistance, Viral , Hepacivirus , Molecular Dynamics Simulation , Mutation , Sofosbuvir , Viral Nonstructural Proteins , Antiviral Agents/pharmacology , Antiviral Agents/chemistry , DEAD-box RNA Helicases , Drug Resistance, Viral/genetics , Hepacivirus/drug effects , Hepacivirus/genetics , Hepacivirus/enzymology , Nucleoside-Triphosphatase , Serine Endopeptidases , Serine Proteases , Sofosbuvir/pharmacology , Viral Nonstructural Proteins/chemistry , Viral Nonstructural Proteins/genetics , Viral Nonstructural Proteins/metabolism , Viral Proteases
16.
J Antimicrob Chemother ; 79(5): 1153-1156, 2024 May 02.
Article in English | MEDLINE | ID: mdl-38558010

ABSTRACT

OBJECTIVES: The in vivo selection of E157Q plus R263K has not been reported in patients treated with coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). To the best of our knowledge, we hereby report the first case of high-grade INSTI resistance associated with the presence of these aminoacidic substitutions in a treatment-experienced HIV patient treated with BIC/FTC/TAF. METHODS: Clinical case report and review of the literature. RESULTS: A heavily treatment-experienced patient was switched to BIC/FTC/TAF due to drug-drug interactions after being diagnosed with disseminated Mycobacterium avium-intracellulare disease. He had been treated before with raltegravir with poor adherence. No mutations in the integrase gene were detected 1 year after finishing treatment with raltegravir. Months after being switched to BIC/FTC/TAF, and again with poor adherence documented, virological failure (VF) was detected. The polymorphic substitution E157Q and the resistance mutation R263K in the integrase gene were detected, as well as M184V, among other mutations in the reverse transcriptase gene. The patient is currently being treated with dolutegravir q12h plus boosted darunavir along with directly observed treatment, and for the first time in 20 years, plasmatic viral load values are below 100 copies/mL. CONCLUSIONS: This case illustrates that the combination of E157Q and R263K plus M184V can be selected in vivo in a clinical scenario of poor adherence with BIC/FTC/TAF, although it is a very rare phenomenon. Previous VF with first-generation integrase strand transfer inhibitors (INSTIs) should be kept in mind when switching patients to second-generation INSTIs.


Subject(s)
Amides , Drug Resistance, Viral , Emtricitabine , HIV Infections , Heterocyclic Compounds, 3-Ring , Heterocyclic Compounds, 4 or More Rings , Piperazines , Pyridones , Tenofovir , Humans , Male , Adenine/analogs & derivatives , Adenine/therapeutic use , Alanine/therapeutic use , Amides/therapeutic use , Amino Acid Substitution , Anti-HIV Agents/therapeutic use , Drug Combinations , Drug Resistance, Viral/genetics , Emtricitabine/therapeutic use , Heterocyclic Compounds, 3-Ring/therapeutic use , Heterocyclic Compounds, 3-Ring/administration & dosage , Heterocyclic Compounds, 4 or More Rings/therapeutic use , Heterocyclic Compounds, 4 or More Rings/administration & dosage , HIV Infections/drug therapy , HIV Infections/complications , HIV Integrase/genetics , HIV Integrase Inhibitors/therapeutic use , Mutation, Missense , Piperazines/therapeutic use , Pyridones/therapeutic use , Tenofovir/therapeutic use , Tenofovir/analogs & derivatives
17.
Emerg Infect Dis ; 30(6): 1289-1291, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38669127

ABSTRACT

Using the GISAID EpiCoV database, we identified 256 COVID-19 patients in Japan during March 31-December 31, 2023, who had mutations in the SARS-CoV-2 nonstructural protein 5 conferring ensitrelvir resistance. Ongoing genomic surveillance is required to monitor emergence of SARS-CoV-2 mutations that are resistant to anticoronaviral drugs.


Subject(s)
Antiviral Agents , COVID-19 , Drug Resistance, Viral , Mutation , SARS-CoV-2 , Humans , Japan/epidemiology , SARS-CoV-2/genetics , COVID-19/epidemiology , COVID-19/virology , Drug Resistance, Viral/genetics , Antiviral Agents/therapeutic use , Antiviral Agents/pharmacology , Male , Female , Middle Aged , Aged , Adult , Viral Nonstructural Proteins/genetics , COVID-19 Drug Treatment , Indazoles , Triazines , Triazoles
18.
J Virol Methods ; 327: 114939, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38604585

ABSTRACT

Despite increasing scale-up of antiretroviral therapy (ART) coverage, challenges related to adherence and HIV drug resistance (HIVDR) remain. The high cost of HIVDR surveillance is a persistent challenge with implementation in resource-constrained settings. Dried blood spot (DBS) specimens have been demonstrated to be a feasible alternative to plasma or serum for HIVDR genotyping and are more suitable for lower resource settings. There is a need for affordable HIVDR genotyping assays which can amplify HIV-1 sequences from DBS specimens, particularly those with low viral loads, at a low cost. Here, we present an in-house assay capable of reliably amplifying HIV-1 protease and partial reverse transcriptase genes from DBS specimens, which covers the complete World Health Organization 2009 list of drug resistance mutations under surveillance. DBS specimens were prepared using whole blood spiked with HIV-1 at concentrations of 10,000, 5000, 1000, and 500 copies/mL (n=30 for each concentration). Specimens were tested in triplicate. A two-step approach was used consisting of cDNA synthesis followed by nested PCR. The limit of detection of the assay was calculated to be approximately 5000 (95% CI: 3200-10,700) copies/mL for the protease gene and 3600 (95% CI: 2200-10,000) copies/mL for reverse transcriptase. The assay was observed to be most sensitive with higher viral load specimens (97.8% [95% CI: 92.2-99.7]) for both protease and reverse transcriptase at 10,000 copies/mL with performance decreasing with the use of specimens with lower viral loads (46.7% [36.1-57.5] and 60.0% [49.1-70.2] at 500 copies/mL for protease and reverse transcriptase, respectively). Ultimately, this assay presents a promising opportunity for use in resource-constrained settings. Future work should involve validation under field conditions including sub-optimal storage conditions and preparation of DBS with fingerprick blood in order to accurately reflect real-world collection scenarios.


Subject(s)
Drug Resistance, Viral , HIV Infections , HIV Protease , HIV Reverse Transcriptase , HIV-1 , Mutation , Humans , HIV-1/genetics , HIV-1/drug effects , HIV-1/isolation & purification , Drug Resistance, Viral/genetics , HIV Infections/virology , HIV Infections/drug therapy , HIV Reverse Transcriptase/genetics , HIV Protease/genetics , Dried Blood Spot Testing/methods , Specimen Handling/methods , Viral Load , Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use , Genotyping Techniques/methods , Genotype , Sensitivity and Specificity
19.
BMC Infect Dis ; 24(1): 316, 2024 Mar 14.
Article in English | MEDLINE | ID: mdl-38486188

ABSTRACT

INTRODUCTION: In 2022, the WHO reported that 29.8 million people around the world were living with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25| 375 people in Gabon (54% of all those living with HIV in the country). The literature reports a frequency of therapeutic failure with first-line antiretrovirals (ARVs) of between 20% and 82%. Unfortunately, data relating to the failure of second-line ARVs are scarce in Gabon. This study aims to determine the profiles of HIV drug resistance mutations related to protease inhibitors in Gabon. METHODOLOGY: Plasma from 84 PLHIV receiving ARVs was collected from 2019 to 2021, followed by RNA extraction, amplification, and sequencing of the protease gene. ARV resistance profiles were generated using the Stanford interpretation algorithm version 8.9-1 ( https://hivdb.stanford.edu ) and statistical analyses were performed using EpiInfo software version 7.2.1.0 (CDC, USA). RESULTS: Of 84 HIV plasma samples collected from 45 men and 39 women, 342 mutations were detected. Of these, 43.3% (148/342) were associated with nucleoside reverse transcriptase inhibitors (NRTIs), 30.4% (104/342) with non-nucleoside reverse transcriptase inhibitors (NNRTIs), and 26.3% (90/342) with protease inhibitors (PIs). Most NRTI mutations were associated with thymidine analogues (TAMs) (50.7%; 75/148), including T215F/V (14.9%; 22/148), D67DN/E/G/N/T (10.1%; 15/148), M41L (9.5%; 14/148), and K70E/KN/S/R (9.5%; 14/148). Resistance mutations related to non-TAM NRTIs (33.1%; 49/148) were M184V (29.1%; 43/148), and L74I/V (8.1%; 12/148). NNRTI mutations were predominantly K103N/S (32.7%; 34/104), V108I (10.6%; 11/104), A98G (10.6%; 11/104), and P225H (9.6%; 10/104). Minor mutations associated with PIs (60.0%; 54/90) were predominantly K20I (15.6%; 14/90) and L10F/I/V (14.5%; 13/90). The major mutations associated with PIs (40.0%; 36/90) were M41L (12.2%; 11/90), I84V (6.7%; 06/90), and V82A (6.7%; 06/90). The four most prescribed therapeutic regimens were TDF + 3TC + LPV/r (20.3%; 17/84), ABC + DDI + LPV/r (17.9%; 15/84), TDF + FTC + LPV/r (11.9%; 10/84), and ABC + 3TC + LPV/r (11.9%; 10/84). CONCLUSION: This study revealed that HIV drug resistance mutations are common in Gabon. The major mutations associated with PIs were M41L, I84V, and V82A. There is a need for access to new NRTIs, NNRTIs, and PIs for a better therapeutic management of PLHIV in Gabon.


Subject(s)
Anti-HIV Agents , HIV Infections , HIV-1 , Male , Humans , Female , Reverse Transcriptase Inhibitors/therapeutic use , Anti-HIV Agents/therapeutic use , Anti-HIV Agents/pharmacology , HIV Infections/drug therapy , HIV Protease/genetics , Gabon , HIV-1/genetics , Anti-Retroviral Agents/therapeutic use , Protease Inhibitors/therapeutic use , Mutation , Drug Resistance, Viral/genetics
20.
Am J Trop Med Hyg ; 110(4): 713-718, 2024 Apr 03.
Article in English | MEDLINE | ID: mdl-38442417

ABSTRACT

India has the third-largest number of people living with HIV (PLHIV) in the world. A national program provides free access to standard uniform antiretroviral therapy. However, the program is not monitored by comprehensive drug resistance surveys. The aim of this study was to determine the prevalence of HIV drug resistance mutations (DRMs) among treatment-naive PLHIV in a large antiretroviral treatment center of the national program. This cross-sectional study was done in 2017 and involved 200 consecutive treatment-naive PLHIV. A target fragment of 1,306 bp in the reverse transcriptase and protease regions was amplified. Identification of mutations and drug resistance interpretation was done by HIV Genotypic Resistance Interpretation and International Antiviral Society-USA list. Sequencing was successful in 177 samples. The majority (98.8%; 175/177) belonged to subtype C. Nineteen of 177 patients (10.7%; 95% CI: 6.2%-15.3%) had at least one major DRM. The prevalence of non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations was 10.2% (18/177). The most frequent mutations were E138A/K, A98G, K103N, V179D, and K101H/E. The prevalence of nucleoside reverse transcriptase inhibitor (NRTI) mutations was 1.1% (2/177). None of the samples had major protease inhibitor resistance mutations. The prevalence of NNRTI mutations in this study was >10%, crossing the threshold recommended by the WHO to change the NNRTI-based first-line regimen to non-NNRTI based. In 2021, the national program replaced efavirenz with dolutegravir in the first-line regimen of tenofovir, lamivudine, and efavirenz. As the majority (64%) of PLHIV in India are accessing free ART from the national program, this study highlights the need for regular nationally representative drug resistance surveys for optimizing antiretroviral regimens in the program.


Subject(s)
Alkynes , Anti-HIV Agents , Cyclopropanes , HIV Infections , HIV-1 , Humans , Reverse Transcriptase Inhibitors/pharmacology , Reverse Transcriptase Inhibitors/therapeutic use , Prevalence , Tertiary Care Centers , Cross-Sectional Studies , HIV-1/genetics , Benzoxazines/therapeutic use , HIV Infections/drug therapy , HIV Infections/epidemiology , Anti-Retroviral Agents/therapeutic use , Mutation , Drug Resistance, Viral/genetics , Anti-HIV Agents/therapeutic use , Anti-HIV Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...